Microbix Biosystems Inc. (TSX:MBX)
Canada · Delayed Price · Currency is CAD | Market Cap | 41.09M +17.8% |
| Revenue (ttm) | 15.40M -27.1% |
| Net Income | -4.88M |
| EPS | -0.04 |
| Shares Out | 136.97M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 31,087 |
| Open | 0.2950 |
| Previous Close | 0.2900 |
| Day's Range | 0.2950 - 0.3000 |
| 52-Week Range | 0.2100 - 0.3250 |
| Beta | 0.54 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Dec 18, 2026 |
About Microbix Biosystems
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures a wide range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays, quality assessment, and diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for enabling the collection of p... [Read more]
Financial Performance
Financial StatementsNews
Microbix Biosystems Transcript: Planet MicroCap Showcase: Toronto 2026
Diagnostics growth is supported by expanded quality-control products and qualification as a supplier to five of the 10 largest diagnostics firms. FY2026 revenue is expected at CAD 16.5M–17M; Kinlytic revenue is targeted from 2028.
Microbix Biosystems reviews new U.S. tariffs on Canada
Microbix Biosystems (MBXBF) announces that it is reviewing the effects of recent changes to United States tariffs on Canada being imposed via Presidential proclamation using provisions of Section 338 ...
Microbix Biosystems presents results of vaginal matrix at IPVS 2026
Microbix Biosystems (MBXBF) will be attending IPVS 2026 and presenting results of a novel synthetic vaginal matrix designed to assist with validation and ongoing quality management of HPV molecular as...
Microbix Attending & Presenting at IPVS 2026
Presenting Results of Novel Product for Validation & QC of HPV Assays MISSISSAUGA, ON / ACCESS Newswire / October 19, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences...
Microbix Making Keynote Presentation at Masters Summit 2026
Discussing its Successful Electronic Quality Management System (eQMS) Onboarding MISSISSAUGA, ON / ACCESS Newswire / October 8, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF), Microbix®), a li...
Microbix Presenting at Cantech Investment Conference
Meetings with Growth-Oriented Investors on October 8, 2026 MISSISSAUGA, ON / ACCESS Newswire / October 6, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF) (Microbix®), a life sciences innovator...
Microbix Presenting at Muskoka Capital Event
Meetings with Growth-Oriented Investors, September 25 to 27, 2026 MISSISSAUGA, ON / ACCESS Newswire / September 23, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF)(Microbix®), a life sciences ...
Microbix Biosystems Slides: Corporate presentation
Microbix Biosystems has posted slides in relation to its latest quarterly earnings report, which was published on September 23, 2026.
Microbix qualifies as supplier for five major Dx Test-Makers product lines
Microbix Biosystems (MBXBF) announces that it has completed formal qualification to become a supplier for five in-vitro diagnostics manufacturers. “Each of these five Dx Test-Makers are considered to ...
Microbix Qualifies as Supplier for Five Major Dx Test-Makers Product Lines for Support of Leading IVD Manufacturers
MISSISSAUGA, ON / ACCESS Newswire / September 9, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF)(Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it has complet...
Microbix Biosystems reports Q3 EPS (C$0.006) vs. (C$0.012) last year
Reports Q3 revenue C$4.06M vs. C$3.47M last year. The company said, “Results for Q3 and YTD continue to demonstrate the results of the Company’s continuing work to rebuild revenues back…
Microbix Biosystems says ‘agressively pursuing’ new client programs
The company said, “Microbix is aggressively pursuing new client programs and new clients, while continuing to add to its portfolio of products and services, and its capabilities. It thereby intends…
Microbix Biosystems Earnings Call Transcript: Q3 2026
Q3 saw 17% year-over-year revenue growth, improved gross margins, and strong cash reserves. Operational efficiencies, B2C sales growth, and progress on major projects like Kinlytic and QAPs commercialization support a positive outlook for Q4.
Microbix Biosystems MD&A: Q3 2026
Microbix Biosystems filed a regulatory document on August 13, 2026 disclosing important business information.
Microbix Biosystems Report: Q3 2026
Microbix Biosystems published a report on August 13, 2026 containing material business information for investors and shareholders.
Microbix Biosystems Earnings release: Q3 2026
Microbix Biosystems released its Q3 2026 earnings on August 13, 2026, summarizing the period's financial results.
Microbix Reports Results for Q3 Fiscal 2026
Q3 Revenues of $4.1 million and Controlled Net Loss MISSISSAUGA, ON / ACCESS Newswire / August 13, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufa...
Microbix Schedules Release of Results for Q3 Fiscal 2026
Results Release and Webinar Discussion on Morning of August 13, 2026 MISSISSAUGA, ON / ACCESS Newswire / August 6, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF), (Microbix®), a life sciences ...
Microbix Biosystems reports Q2 EPS (C$0.01) vs. C$0.00 last year
Reports Q2 revenue C$3.38M vs. C$5.32M last year. The company said, “Results for Q2 and H1 demonstrated early results of the Company’s continuing work to rebuild revenues back to profitability…
Microbix Biosystems says ‘agressively pursuing’ new client programs
The company said, “Microbix is aggressively pursuing new client programs and new clients, while continuing to add to its portfolio of products and services, and its capabilities. It thereby intends…
Microbix Biosystems Earnings Call Transcript: Q2 2026
Q2 saw revenues fall below breakeven due to a sharp drop in Chinese sales and delayed antigen orders, but non-China business grew and cost controls remain strong. QAPs revenues are expected to rebound, and Kinlytic's launch is on track for 2028, with a solid cash position supporting ongoing investments.
Microbix Biosystems Earnings release: Q2 2026
Microbix Biosystems released its Q2 2026 earnings on May 14, 2026, summarizing the period's financial results.
Microbix Biosystems Report: Q2 2026
Microbix Biosystems published a report on May 14, 2026 containing material business information for investors and shareholders.
Microbix Biosystems MD&A: Q2 2026
Microbix Biosystems filed a regulatory document on May 14, 2026 disclosing important business information.
Microbix Reports Results for H1 & Q2 2026
H1 Revenues of $7.6 million and Controlled Net Loss MISSISSAUGA, ON / ACCESS Newswire / May 14, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF)(Microbix®), a life sciences innovator, manufactur...